Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey guys,
I consider our news today as a positive but it looks like the
only other drug approved for NK was 72 percent successful in
healing. See part of an article I copied below.
However , this proves that TB4 is a healing agent and this bodes
well for the Dry Eye trial that is under way. I would think that
any big pharmaceuticals that have had an eye out here would
be very happy with the results of this trial.
Now we wait for the completion of the Arise 3 to finish. We
we’re looking at a May finish till Covid 19 came around but
maybe we get results by the end of summer fingers crossed.
I think I will add some more here while the price is still cheap.
We have a winner here IMO.
See what the competition did below.
Have a great day !
Published: Aug 23, 2018
- Oxervate is the first-ever application of a human nerve growth factor as drug or treatment, and is the first-ever topical biologic medication approved in ophthalmology.
- The first treatment specifically indicated for neurotrophic keratitis (NK), Oxervate has a mechanism of action that targets the root pathology of the disease.
- Oxervate has the potential to resolve the rare and progressive eye disease with one eight-week cycle of treatment; in clinical trials, approximately 72 percent of patients who used Oxervate achieved complete corneal healing after eight weeks of treatment, and of these patients, approximately 80 percent remained healed after one year.
- Oxervate was authorized by the European Medicines Agency (EMA) in 2017 and represents Dompé's first approved therapy in the United States, where Oxervate received Orphan Drug Designation, Fast Track Status, and Breakthrough Therapy Designation, which led to Priority Review.
MILAN and SAN BRUNO, Calif., Aug. 22, 2018 /PRNewswire/ -- Dompé today announced that the U.S. Food and Drug Administration (FDA) has approved OxervateTM (cenegermin-bkbj ophthalmic solution), a breakthrough therapy for neurotrophic keratitis (NK), a rare and progressive eye disease that can lead to corneal scarring and vision loss.1
It was a great week! The company says we will have
NK results in a few months then an update hopefully
stating that the Arise 3 is completely enrolled say by
end of May with final results on that by the first of
August. If NK is good some big pharma may go
ahead and pull the trigger and buy RGRX out
knowing that TB4 actually heals something.
Either way our long wait should be over this
year. Enjoy the weekend ( Stub and 56) !!
I bought my first shares in 2010 but I don’t remember the $6 or $8
prices. I’m not clear on where the price might go on an Arise 3 win
other than way up from here. I would like to see NK or EB results
over the next couple months and then an Arise 3 update in April
just to keep the price moving up at a steady clip. I’m feeling
like RGRX will have a buyer before the ball drops in Times
Square in 2021:). IMHO.
Yes. I heard about the OTC drops and TB4 today from a poster
on the Yahoo board! I got into this stock 10 years ago when
the symbol was RGN. What lured me in was talk about The Henry
Ford work with TB4 and MS. My wife was diagnosed with it
11 years ago and the people with MS are looking for anything
that might help. Not sure if we will ever see this used for MS
but it looks like it’s going to definitely help some dry eye
folks in the not to distant future. I’m not much of a bio guy
either but there can be some big fast moves when all the
stars align . Good luck to you Stuborn.
The ARISE-2 study, which was conducted together with Ora, Inc., demonstrated a number of statistically significant improvements in both signs and symptoms of dry eye syndrome with 0.1% RGN-259 versus placebo, while showing excellent safety, comfort, and tolerability profiles. The ocular discomfort symptom showed a statistically significant reduction in the RGN-259-treated group at day 15 as compared to placebo (p=0.0149) in the change from baseline. For sign, RGN-259 also improved the dry eye
Stubborn I think we are about to make some money here. IMO.
Just duplicating the above Arise 2. Lots of big money behind the scene here.
Arise 3 is well underway.
Enjoy the ride.
JP Morgan Conference. :) sorry not enough coffee yet.
Hey there boy. It was a great week for RGRX. Must have
been some interest generated at the Morgan Stanley conference
.Next week should be interesting.
Yes Chiro- You can find some of my older post on here on I hub. I bought in years ago when this was in the $3.00 range and sold for a loss around $2. This was during the Brad Poulous days. I kept my eye on the stock for a while and thought it was going out of business. I got back in when it looked like John might pull this one off and turn it around. I own a little under 40,000 shrs with a cost basis of 4 cents. I watch this board occasionally and enjoy your post along with Brads and D theG. This is just a speculative buy based on some long ago succes from Johm. I still believe he can pull it off but I want to see some real sales, profits and on time reports. Jumping back in on this was just a gut feeling ( I have lost many times because of this ). However if the news that is coming out all comes to fruition we could all
make a few dollars and then move on to the next big deal. Good luck Chiro.
Hedge- I'm not sure if all this pump is going to take us to .10c just to see a big dump back to .01. I am here because of John's past success and hope that we see a 3 to 5 dollar stock based on real sales, profits ,on time reporting and a return to a major exchange. I think if you have some money to play with you might just make a few dollars here. I like the inovative solutions idea best of all. Everyone (business and consumers want energy savings) and being tied to someone like inovative is a good move.
I will probably pick up a little more at the 3 to 4 cent range and see where we end up a year from now. Good luck to all.
I'm not sure TM will wait till June to settle with CLYW.They have the money to step up and push Diac out of the picture any time they are ready. But you are correct about this going to 6c. I don't like to cheer a stock down that I own,but I would pick up another truck load of shares if this hits the 4 to 6 c range.
Yes-I think we saw more than a few retail investors here. We should see a nice bump up tommorow as more big money comes in.
Thanks for the update! I look forward to hearing the PR that John did fine and is making a full recovery.
SUN- I think it is out of respect that they are not asking. I have been through the open heart bypass several times with family members and it has always been 4 to 6 week before they are back on their feet. Also as I have said before John could have bailed out here a long time ago and left you with less than you have now. Give John and his family the respect they deserve and be thankful you have what you have. I don't see John as someone to give up easy. He will be back stronger than ever. Oh and by the way I just hope you can apologize as well as you complain when John turns this around._Merry Christmas SUN.
Hey dude. I thought you were out of here? Post 3767.
Chiro-If we can get someones shares cheaper (3 to 5 cents) I will buy many. I was here when this stock was $3.00 and remember some of the deals gone bad in the wireless mess. I took a loss in the low two dollar range when things started looking bad,but kept this on my watch list just to see what might happen. I bought back in at 5 cents. John could have bailed out on this thing a long time ago but stuck it out. I believe he will stick the proverbial feather in his cap on this one as a great comeback deal and make a lot of money doing it. Albert Pope was the man to get and John brought him on board. Having great leaders in the right spot is what it takes. There is a lot of work ahead for these guys. I have know idea how high this stock can go but I still believe that anything below .10 is a great buy. I have been wrong many times before and may get bit again here but I just don't think so. It seems like the name change at the first of the year would be a good thing. These small cap jobs do very well in January. Good luck to all.
Well said inprudent. I believe that the best is yet to come for
WLSA. I not sure how long we will have to wait but when I buy shares at 2 to 3 cents I can be very patient. And yes John
still knows how to make money. This could be one of his best
when it starts rolling. Get some shares and hang on for the
ride. It could be fun.